aripiprazole has been researched along with piperidines in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 11 (35.48) | 29.6817 |
| 2010's | 16 (51.61) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Fujikawa, M; Furukawa, T; Inoue, T; Nagashima, M; Yamada, K | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Carlsson, A; Carlsson, ML; Nilsson, M | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Burris, KD; Kikuchi, T; Miwa, T; Mori, T; Stark, A; Tadori, Y; Tottori, K | 1 |
| Chen, R; Johnson, JL; Jordan, S; Kambayashi, J; Kikuchi, T; Kitagawa, H; McQuade, R; Regardie, K; Tadori, Y | 1 |
| Corsini, GU; Maggio, R; Millan, MJ; Novi, F | 1 |
| Poyurovsky, M; Weizman, A; Weizman, R | 1 |
| Abe, M; Egashira, N; Fujiwara, M; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Arnt, J; Bétry, C; Etievant, A; Haddjeri, N | 1 |
| Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 1 |
| Greenway, LL; Kuppuswamy, PS; Lauterbach, EC | 1 |
| Calas, AG; Goursaud, S; Hermans, E; Jeanjean, AP; Koener, B; Maloteaux, JM; Van De Stadt, M | 1 |
| Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Goracci, L; Neri, A; Oprea, TI | 1 |
| Carlsson, A; Carlsson, ML; Johansson, AM; Rung, E; Rung, JP; Svensson, K | 1 |
| Knoepflmacher, D; Shapley, L; Turner, EH | 1 |
| Lowry, JP; O'Connor, JJ | 1 |
| Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
| Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
| Ma, GF; Ortiz, J; Raivio, N; Sabrià, J | 1 |
| Futamura, T; Hashimoto, K; Ishima, T; Kikuchi, T; Ohgi, Y; Yoshimi, N | 1 |
| Canals, M; Capuano, B; Charlton, SJ; Christopoulos, A; Coudrat, T; Donthamsetti, P; Javitch, JA; Klein Herenbrink, C; Lane, JR; Scammells, PJ; Sexton, PM; Shonberg, J; Sykes, DA | 1 |
| Ashraf, NS; Cook, D; Costa, MDC; Dharia, RM; Dulchavsky, M; Fischer, S; Gestwicki, JE; Ivanova, MI; Joshi, G; Larsen, MJ; McQuade, TJ; Ouyang, M; Paulson, HL; Schapka, E; Sun, D; Todi, SV; Yang, Y | 1 |
| Hashimoto, N; Kuksumi, I; Miyamoto, T; Miyazaki, A; Toyomaki, A | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Aguiar, DC; Asth, L; Briânis, RC; Iglesias, LP; Marçal, AP; Moreira, FA; Soares, NP | 1 |
| Fujita, K; Iga, JI; Inada, K; Ishigooka, J; Iwata, N; Kanda, Y; Kikuchi, Y; Kishi, T; Kishimoto, T; Koretsune, S; Nakagome, K; Ohi, K; Ohmori, T; Sekiyama, K; Shichijo, T; Tabuse, H; Terada, H; Tsutsumi, Y | 1 |
5 review(s) available for aripiprazole and piperidines
| Article | Year |
|---|---|
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Schizophrenia: from dopamine to glutamate and back.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia | 2004 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
4 trial(s) available for aripiprazole and piperidines
| Article | Year |
|---|---|
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Piperazines; Piperidines; Remission Induction; Schizophrenia; Social Interaction; Treatment Outcome | 2022 |
22 other study(ies) available for aripiprazole and piperidines
| Article | Year |
|---|---|
Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Azepines; Dopamine Agonists; Drug Synergism; Male; Oxidopamine; Piperazines; Piperidines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine; Stereotyped Behavior; Sympathectomy, Chemical; Yawning | 1996 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; DNA, Complementary; Dopamine; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Humans; Lisuride; Piperazines; Piperidines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Risperidone; Transfection; Tritium | 2005 |
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium Signaling; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoblotting; Lisuride; MAP Kinase Signaling System; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Phosphorylation; Piperazines; Piperidines; Quinolones; Raclopride; Receptors, Dopamine D2; Schizophrenia; Time Factors; Transfection | 2007 |
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzoxazoles; Carrier Proteins; Chlorocebus aethiops; Clozapine; COS Cells; Cricetinae; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Piperazines; Piperidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Transfection | 2007 |
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea | 2008 |
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Catalepsy; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Indoles; Ketanserin; Male; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Piperidines; Postural Balance; Psychomotor Performance; Pyridines; Quinolones; Quinpirole; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists | 2008 |
Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Topics: Action Potentials; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Indoles; Male; Neurons; Piperazines; Piperidines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Sulfones; Tetrahydronaphthalenes; Ventral Tegmental Area | 2009 |
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia | 2010 |
Differential pharmacological responses of catatonia-like signs in frontotemporal dementia.
Topics: Aged; Amantadine; Antipsychotic Agents; Aripiprazole; Benzothiazoles; Catatonia; Citalopram; Clinical Trials as Topic; Dibenzothiazepines; Donepezil; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Frontotemporal Dementia; Humans; Hypnotics and Sedatives; Indans; Lorazepam; Memantine; Middle Aged; Nootropic Agents; Piperazines; Piperidines; Pramipexole; Quetiapine Fumarate; Quinolones; Selective Serotonin Reuptake Inhibitors | 2010 |
Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
Topics: Animals; Apomorphine; Aripiprazole; Buffers; Catalepsy; Cell Membrane; Cerebral Cortex; Corpus Striatum; Domperidone; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Antagonism; Drug Partial Agonism; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Hippocampus; Male; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Stereotyped Behavior; Up-Regulation | 2011 |
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
Topics: Animals; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B, Member 1; Butyrophenones; Cell Line, Tumor; Cell Membrane Permeability; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Mice; Models, Molecular; Molecular Structure; Piperazines; Piperidines; Protein Binding; Quantitative Structure-Activity Relationship; Quinolones | 2011 |
Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.
Topics: Animals; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Hyperprolactinemia; Lactotrophs; Male; Methyltyrosines; Piperazines; Piperidines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine | 2011 |
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Databases, Factual; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Publication Bias; Pyrimidines; Quetiapine Fumarate; Quinolones; Risperidone; United States; United States Food and Drug Administration | 2012 |
A comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-PPP with quinpirole on stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry in vitro.
Topics: Animals; Aripiprazole; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Partial Agonism; In Vitro Techniques; Male; Piperazines; Piperidines; Quinolones; Quinpirole; Rats; Rats, Wistar | 2012 |
Agonist and antagonist effects of aripiprazole on D₂-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone.
Topics: Animals; Aripiprazole; Autoreceptors; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Male; Piperidines; Potassium; Presynaptic Terminals; Quinpirole; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2014 |
Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Topics: Animals; Aripiprazole; Boron Compounds; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; HSP90 Heat-Shock Proteins; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Nerve Growth Factor; Neurites; Oxazoles; PC12 Cells; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Agents; Thiophenes | 2015 |
The role of kinetic context in apparent biased agonism at GPCRs.
Topics: Animals; Aripiprazole; CHO Cells; Cricetulus; Dopamine; Dopamine Agonists; Indoles; Kinetics; Ligands; Piperazines; Piperidines; Principal Component Analysis; Protein Stability; Receptors, Dopamine D2 | 2016 |
Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.
Topics: Animals; Animals, Genetically Modified; Antipsychotic Agents; Aripiprazole; Ataxin-3; Brain; Disease Models, Animal; Drosophila; Drug Evaluation, Preclinical; Gene Expression Regulation; HEK293 Cells; Humans; Machado-Joseph Disease; Mice; Mutant Proteins; Nerve Tissue Proteins; Organ Culture Techniques; Peptides; Piperidines; Pyrans; Pyrazoles | 2016 |
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.
Topics: Adult; Anticipation, Psychological; Antipsychotic Agents; Aripiprazole; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Piperidines; Prefrontal Cortex; Reward; Schizophrenia; Ventral Striatum | 2018 |
Effects of the monoamine stabilizer, (-)-OSU6162, on cocaine-induced locomotion and conditioned place preference in mice.
Topics: Animals; Aripiprazole; Behavior, Animal; Cocaine; Conditioning, Psychological; Dose-Response Relationship, Drug; Drug-Seeking Behavior; Locomotion; Male; Mice; Piperidines | 2021 |